Cargando…
Negative trials in ovarian cancer: is there such a thing as too much optimism?
Recently, two clinical trials of novel agents in metastatic ovarian cancer were published: a phase 3 study of nintedanib and a phase 2 study of volasertib. There seemed to be discordance between the results and conclusions in the publication of both these trials. Despite not very optimistic results,...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cancer Intelligence
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990052/ https://www.ncbi.nlm.nih.gov/pubmed/27594913 http://dx.doi.org/10.3332/ecancer.2016.ed58 |